{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:29:37Z","timestamp":1785598177726,"version":"3.56.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pulmonary arterial intimal sarcoma (PAIS) is a rare malignant mesenchymal tumor often associated with an unfavorable prognosis and lacks a standardized treatment approach to date. This report presents a notable case of PAIS treated with neoadjuvant therapy involving anlotinib concomitantly administered with chemotherapy of ifosfamide and pirarubicin, which resulted in a favorable outcome. A 38-year-old man was admitted to our hospital with chest tightness, cough, and dyspnea, all of which had persisted for more than a week. Initial evaluation via chest computed tomography (CT) revealed a sizable posterior mediastinal tumor measuring 11.9 \u00d7 7.6 cm. A CT-guided biopsy was performed, and pathological findings confirmed the diagnosis of PAIS. Efficacy evaluation showed slow progress after one cycle of chemotherapy with ifosfamide and pirarubicin. To enhance treatment outcomes, we incorporated anlotinib as a neoadjuvant therapy alongside ifosfamide and pirarubicin. Subsequent CT imaging demonstrated a significant reduction in tumor size, and the patient experienced notable alleviation of symptoms. The patient then underwent surgery, radiation, and subsequently, maintenance treatment with anlotinib for one year. No severe drug-related side effects were observed. The patient achieved progression-free survival of 25 months following administration of anlotinib. Thus, the combination of anlotinib with ifosfamide and pirarubicin demonstrated significant efficacy and safety. This approach holds promise as an effective therapeutic strategy for managing unresectable, locally advanced, or advanced PAIS. However, further clinical studies are necessary to validate these findings.<\/jats:p>","DOI":"10.3389\/fonc.2025.1507281","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:34:35Z","timestamp":1740555275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of anlotinib and chemotherapy combination as neoadjuvant therapy in the treatment of pulmonary artery intimal sarcoma: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Gai","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"B1","volume-title":"WHO classification of tumours, Thoracic tumours","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40001-021-00568-w","article-title":"A case report of primary pulmonary artery intimal sarcoma","volume":"26","author":"Bai","year":"2021","journal-title":"Eur J Med Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3892\/ol.2022.13470","article-title":"Pulmonary thromboembolic disease or pulmonary artery intimal sarcoma: Case report and literature review","volume":"24","author":"Shao","year":"2022","journal-title":"Oncol Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i16.3960","article-title":"Undifferentiated intimal sarcoma of the pulmonary artery: A case report","volume":"9","author":"Li","year":"2021","journal-title":"World J Clin cases"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2018.36.15_suppl.11503","article-title":"Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo-controlled and multi-centered clinical trial","volume":"36","author":"Chi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024699","article-title":"Pulmonary artery intimal sarcoma mimicking pulmonary thromboembolism: A case report","volume":"100","author":"Li","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3760\/cma.j.cn112151-20200413-00313","article-title":"Clinicopathological characteristics of pulmonary artery intimal sarcoma","volume":"50","author":"Wang","year":"2021","journal-title":"Chin J Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000476036","article-title":"Single-center experience with intimal sarcoma, an ultra-orphan, commonly fatal mesenchymal Malignancy","volume":"40","author":"Van Dievel","year":"2017","journal-title":"Oncol Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02250-6","article-title":"Pulmonary artery intimal sarcoma: Case report of a patient managed with multimodality treatment and a comprehensive literature review","volume":"200","author":"Atahan","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.08.018","article-title":"Management of primary pulmonary artery sarcomas","volume":"87","author":"Blackmon","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.5410","article-title":"Breast conservation after neoadjuvant chemotherapy for triple-Negative breast cancer: surgical results from the brighTNess randomized clinical trial","volume":"155","author":"Golshan","year":"2020","journal-title":"JAMA Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.v36.10","article-title":"Repeat resection for recurrence of pulmonary artery intimal sarcoma","volume":"36","author":"Goerlich","year":"2021","journal-title":"J Card Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.rmcr.2021.101414","article-title":"Intimal sarcoma of the pulmonary artery treated with neoadjuvant radiation prior to pulmonary artery resection and reconstruction","volume":"33","author":"Allen","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S426898","article-title":"Research progress on mechanism and management of adverse drug reactions of anlotinib","volume":"17","author":"Li","year":"2023","journal-title":"Drug Des Devel. Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib induces a T cell-Inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v11.11","article-title":"The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.6199","article-title":"Intimal sarcoma of the pulmonary artery treated with pazopanib","volume":"55","author":"Funatsu","year":"2016","journal-title":"Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0419","article-title":"Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase ib\/II study","volume":"13","author":"Koyama","year":"2023","journal-title":"Cancer Discovery"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:34:38Z","timestamp":1740555278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1507281"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1507281","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1507281"}}